Klaudia Elżbieta Niwińska

Klaudia Elżbieta Niwińska

Auto-generated profile, based on publicly available information

Klaudia Elżbieta Niwińska

Independent Public Clinical Hospital named after Prof. W. Orłowski (CMKP), Warszawa, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KNKlaudia Elżbieta Niwińska
Klaudia Elżbieta Niwińska
MBMichał Borowski
Michał Borowski
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
NLNatalia Maria Leśniak
Natalia Maria Leśniak
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AMAleksander Midera
Aleksander Midera
Obesity impairs female fertility through metabolic, endocrine and inflammatory pathways that disrupt ovulation, reduce oocyte competence and impair endometrial receptivity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have become highly effective therapies for weight management and metabolic optimisation, raising interest in their potential reproductive benefits. This narrative review synthesises current mechanistic and clinical evidence on how GLP-1 receptor agonists and tirzepatide may influence reproductive function in women of reproductive age. A literature search was conducted using PubMed, Scopus and Web of Science for peer-reviewed human studies and major reviews published up to December 2025 that evaluated metabolic, endocrine or reproductive outcomes. Available evidence suggests that GLP-1 signalling may influence the hypothalamic–pituitary–ovarian axis, adipokine pathways, oocyte mitochondrial function and endometrial gene expression. Clinical studies indicate that liraglutide and semaglutide improve body weight, insulin resistance and hyperandrogenism, leading to restoration of menstrual regularity and increased ovulation rates, with some reports of improved spontaneous conception and assisted reproduction outcomes. Tirzepatide provides greater metabolic benefits, although fertility-specific data remain limited. Overall, GLP-1–based therapies act primarily as metabolic optimisers that may secondarily enhance fertility, while evidence for direct reproductive effects and periconceptional safety remains insufficient.

2 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
MBMichał Borowski
Michał Borowski
KPKinga Popielarska
Kinga Popielarska
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.

2 January 2026 in Quality in Sport
Verified
Journal Article
Open access
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
MBMichał Borowski
Michał Borowski
KPKinga Popielarska
Kinga Popielarska
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.

3 January 2026 in Quality in Sport
Verified
Journal Article
Open access
JMJulia Agnieszka Michalak
Julia Agnieszka Michalak
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
KPKinga Popielarska
Kinga Popielarska
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.

4 May 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
AMAleksander Midera
Aleksander Midera
KPKinga Popielarska
Kinga Popielarska
KNKlaudia Elżbieta Niwińska
Klaudia Elżbieta Niwińska
NLNatalia Maria Leśniak
Natalia Maria Leśniak
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
MAMonika Augustyn
Monika Augustyn
Background: Sepsis is a life-threatening condition characterised by organ dysfunction caused by a dysregulated host response to infection and remains a major cause of morbidity and mortality worldwide. Early recognition is clinically challenging because initial symptoms are non-specific and commonly used inflammatory markers have limited diagnostic performance. Consequently, there is ongoing interest in biomarkers that enable faster and more accurate identification of sepsis. Aim: To discuss selected sepsis biomarkers: interleukin-6 (IL-6), soluble TREM-1 (sTREM-1), and neutrophil CD64 expression, with particular emphasis on biological mechanisms, clinical utility, and diagnostic limitations. Materials and methods: A narrative review of the literature was undertaken. Publications from 2016 to 2025 indexed in PubMed/MEDLINE, Scopus, and Google Scholar were analysed, including clinical studies, reviews, and meta-analyses. Evidence was assessed with respect to biological mechanisms, diagnostic and prognostic performance, and limitations of the biomarkers. Results: Neutrophil CD64 expression shows high specificity for bacterial infection and sepsis; however, routine use is constrained by limited assay standardisation and the absence of validated cut-off values. IL-6 rises very early and has prognostic value, correlating with the severity of organ dysfunction and mortality risk, but it has low specificity. sTREM-1 reflects activation of the TREM-1 axis and the intensity of the inflammatory response; however, its ability to distinguish sepsis from non-infectious SIRS is limited. Conclusions: None of the reviewed biomarkers should be used as a stand-alone diagnostic test. The greatest clinical value is likely to be achieved with a multiparametric approach that combines clinical assessment and organ dysfunction scores with biomarkers representing different stages of the immune response. This strategy may improve early recognition, risk stratification, and monitoring of sepsis.

25 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
JLJulia Aleksandra Leśniak
Julia Aleksandra Leśniak
NLNatalia Maria Leśniak
Natalia Maria Leśniak
KPKlaudia Martyna Patrzykąt
Klaudia Martyna Patrzykąt
AZAnna Maria Zakrzewska
Anna Maria Zakrzewska
AMAleksander Midera
Aleksander Midera
KJKacper Jaskulski
Kacper Jaskulski
Background. Sleep disorders represent a heterogeneous group of conditions that impair sleep quality, duration, and architecture, leading to significant daytime dysfunction and increased global morbidity. Epidemiological data indicate that approximately 30–40% of adults experience sleep disturbances, including insomnia and obstructive sleep apnea (OSA), which are increasingly recognized as modifiable risk factors for cardiovascular disease (CVD). Aim. The aim of this narrative review was to synthesize current evidence on the association between sleep disorders and major cardiovascular outcomes and to identify the biological mechanisms underlying these relationships. Material and methods. A narrative review of the literature was conducted using PubMed, ScienceDirect, JAMA Network, OUP, and open-access repositories. Epidemiological studies, cohort studies, and meta-analyses evaluating the impact of insomnia, sleep-disordered breathing, and circadian rhythm disturbances on hypertension, coronary artery disease, heart failure, arrhythmias, and stroke were analyzed. Results. The reviewed evidence demonstrates that insomnia and obstructive sleep apnea are consistently associated with an increased risk of cardiovascular diseases, particularly hypertension, atrial fibrillation, coronary artery disease, heart failure, and stroke. The underlying mechanisms include sympathetic nervous system overactivation, oxidative stress, systemic inflammation, endothelial dysfunction, and dysregulation of glucose and lipid metabolism. Conclusions. Sleep disorders have great effects on the cardiovascular system and should be considered independent, modifiable risk factors for CVD. Early diagnosis and treatment of sleep disorders may play a crucial role in cardiovascular disease prevention and risk reduction.